--- type: "Topics" locale: "en" url: "https://longbridge.com/en/topics/100000000768396.md" description: "📢 𝐉𝐔𝐒𝐓 𝐈𝐍: FDA Accepts $Sarepta Therap(SRPT.US) Sarepta's sNDAs for AMONDYS 45 and VYONDYS 53👉 𝐊𝐞𝐲 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬:➤ FDA accepted 𝐒𝐚𝐫𝐞𝐩𝐭𝐚'𝐬 sNDAs for 𝐀𝐌𝐎𝐍𝐃𝐘𝐒 𝟒𝟓 and 𝐕𝐘𝐎𝐍𝐃𝐘𝐒 𝟓𝟑.➤ Applications seek to convert both therapies from 𝐚𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐞𝐝 to 𝐭𝐫𝐚𝐝𝐢𝐭𝐢𝐨𝐧𝐚𝐥 approval.➤ FDA set a 𝐏𝐃𝐔𝐅𝐀 action date of 𝐅𝐞𝐛. 𝟐𝟖, 𝟐𝟎𝟐𝟕.➤ Filings are supported by 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐄𝐒𝐒𝐄𝐍𝐂𝐄 data, real-world evidence, and safety results.➤ ESSENCE missed its 𝐩𝐫𝐢𝐦𝐚𝐫𝐲 𝐞𝐧𝐝𝐩𝐨𝐢𝐧𝐭, but post-hoc analyses favored treatment.➤ VYONDYS 53 was associated with a 𝟕.𝟓-𝐲𝐞𝐚𝐫 delay in nighttime ventilation.➤ AMONDYS 45 was associated with a 𝐬𝐭𝐚𝐭𝐢𝐬𝐭𝐢𝐜𝐚𝐥𝐥𝐲 𝐬𝐢𝐠𝐧𝐢𝐟𝐢𝐜𝐚𝐧𝐭 slowing of lung function decline.➤ More than 𝟏,𝟖𝟎𝟎 patients have received Sarepta's exon-skipping therapies worldwide.👉 𝐖𝐡𝐲 𝐈𝐭 𝐌𝐚𝐭𝐭𝐞𝐫𝐬:➤ Traditional approval could strengthen the therapies' 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 standing and long-term availability.➤ FDA acceptance marks a key 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 milestone for Sarepta's DMD franchise.➤ Positive FDA decisions could support broader 𝐩𝐡𝐲𝐬𝐢𝐜𝐢𝐚𝐧 and payer confidence.👉 𝐄𝐱𝐩𝐞𝐫𝐭 𝐒𝐭𝐚𝐭𝐞𝐦𝐞𝐧𝐭:➤ "The submissions draw on the ESSENCE study and years of published real-world evidence, which together offer a fuller understanding of how these therapies benefit patients and change the progression of disease." — 𝐋𝐨𝐮𝐢𝐬𝐞 𝐑𝐨𝐝𝐢𝐧𝐨-𝐊𝐥𝐚𝐩𝐚𝐜, Ph.D., President of Research and Development and Technical Operations at Sarepta Therapeutics." datetime: "2026-06-30T12:35:40.000Z" locales: - [en](https://longbridge.com/en/topics/100000000768396.md) - [zh-CN](https://longbridge.com/zh-CN/topics/100000000768396.md) - [zh-HK](https://longbridge.com/zh-HK/topics/100000000768396.md) author: "[Hardik Shah](https://longbridge.com/en/profiles/27423834.md)" generator: "portal-rs" --- # 📢 𝐉𝐔𝐒𝐓 𝐈𝐍: FDA Accepts $Sarepta Therap(SRPT.US) Sa… ### Related Stocks - [SRPT.US](https://longbridge.com/en/quote/SRPT.US.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**